180°N - Norwegian Nuclear Medicine Consortium
The 180 °N project is a new national research collaboration led by Universities and University Hospitals in Tromsø, Trondheim and Bergen. Stavanger University Hospital also participates as a partner in one of the projects. The 180 °N project aims to develop methods for various cancer diseases and neurological disorders, and to improve patient stratification and personalized treatment. The research program starts in 2019 and will last until 2025.
Towards the collaborative goals, the Bergen project focuses on the development of radioactive tracers, Tromsø on preclinical testing, and Trondheim on clinical trials. A close cooperation network in the fields of tracer development, pharmacology, chemistry, (radiation) oncology, (radiation) biology, nuclear medicine, immunology, drug development and machine learning are established. State-of-the-art imaging diagnostic equipment is also funded by private gifts from Trond Mohn to the University Hospitals in the three cities. This allows method and routine transfer between institutions, and that the projects can reinforce each other with knowledge and data from their focus fields.
Studies:
Targeting tumor microenvironment Boosting PET-based diagnostics and therapies
WP1: Immuno-PET and lung cancer
WP2 - Radionuclide targeted therapy and imaging in Glioblastoma
WP3 - Phagocyte targeting in breast cancer
WP4 - Advancing oncological PET imaging using machine learning
https://www.ntnu.edu/180n/preclinical-research-troms%C3%B8
Members:
Rune Sundset (Principal investigator)
Financial/grant information:
The 180 °N project is funded by Tromsø Research Foundation and Trond Mohn Foundation, both based on donations from Trond Mohn.
Link to this page